# US 2022/0290161 A1 · Rna-regulated fusion proteins and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0290161 A1
- Document ID: US20220290161A1
- Status: Published application
- Kind: A1
- Application number: 17/637,940
- Filed: 2020-08-31
- Published: 2022-09-15
- Earliest claimed: 2019-08-30
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Samie R. JAFFREY; Jiahui WU
- Web page: https://patentgrep.com/patent/US20220290161A1

## CPC

- C12N 15/62: DNA sequences coding for fusion proteins
- C12Y 113/12007: Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 5/0602: {Vertebrate cells}
- C12N 9/0069: {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/85: for animal cells
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C12Y 111/01011: L-ascorbate peroxidase (1.11.1.11)
- C12Y 113/12: with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
- C12Y 113/12005: Renilla-luciferin 2-monooxygenase (1.13.12.5), i.e. renilla-luciferase
- C12Y 113/12013: Oplophorus-luciferin 2-monooxygenase (1.13.12.13)
- C12Y 201/01043: Histone-lysine N-methyltransferase (2.1.1.43)
- C12Y 603/0401: Biotin--[propionyl-CoA-carboxylase (ATP-hydrolyzing)] ligase (6.3.4.10)
- C12Y 603/04015: Biotin-[acetyl-CoA-carboxylase] ligase (6.3.4.15)
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C07K 2319/61: containing an enzyme fusion for detection (lacZ, luciferase)
- C07K 2319/85: containing an RNA binding domain
- C12N 2310/16: Aptamers
- C12N 2800/107: for mammalian
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure is directed to RNA-regulated fusion proteins comprising a protein of interest and an RNA-regulated destabilization domain. Also disclosed are RNA aptamers that bind specifically to a RNA-regulated destabilization domain. Nucleic acid molecules encoding the RNA-regulated fusion proteins and RNA aptamers and methods of use thereof are also disclosed.

## Claims

### Claim 1

A nucleic acid molecule encoding an RNA-regulated fusion protein, said nucleic acid molecule comprising:
a first nucleic acid sequence encoding a protein of interest and
a second nucleic acid sequence encoding an RNA-regulated destabilization domain, wherein the second nucleic acid sequence is operably coupled to the first nucleic acid sequence.

### Claim 2 (depends on 1)

The nucleic acid molecule according to claim 1, wherein the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor.

### Claim 3 (depends on 2)

The nucleic acid molecule according to claim 2, wherein the protein of interest is a fluorescent protein selected from the group consisting of Green Fluorescent Protein, Enhanced Green Fluorescent Protein (EGFP), Enhanced Yellow Fluorescent Protein (EYFP), Venus, mVenus, Citrine, mCitrine, Cerulean, mCerulean, Orange Fluorescent Protein (OFP), mNeonGreen, moxNeonGreen, mCherry, mTagBFP, Venus, mVenus, mTurquoise, mScarlet, mWasabi, mOrange, and dTomato.

### Claim 4 (depends on 2)

The nucleic acid molecule according to claim 2, wherein the protein of interest is a bioluminescent protein.

### Claim 5 (depends on 4)

The nucleic acid molecule according to claim 4, wherein the bioluminescent protein is selected from the group consisting of luciferase, β-galactosidase, β-lactamase, peroxidase, alkaline phosphatase, β-glucuronidase, and β-glucosidase.

### Claim 6 (depends on 5)

The nucleic acid molecule according to claim 5, wherein the bioluminescent protein is a luciferase selected from the group consisting of Nanoluc luciferase (Nluc), Firefly luciferase, and Renilla luciferase (Rluc).

### Claim 7 (depends on 2)

The nucleic acid molecule according to claim 2, wherein the protein of interest is an enzyme.

### Claim 8 (depends on 7)

The nucleic acid molecule according to claim 7, wherein the enzyme is a biotin ligase.

### Claim 9 (depends on 8)

The nucleic acid molecule according to claim 8, wherein the biotin ligase is selected from the group consisting of TurboID, miniTurbo, and E. coli BirA.

### Claim 10 (depends on 7)

The nucleic acid molecule according to claim 7, wherein the enzyme is a methyltransferase selected from the group consisting of a histone methyltransferase, an N-terminal methyltransferase, a DNA/RNA methyltransferase, a natural product methyltransferase, a non-SAM dependent methyltransferase, or a radical SAM methyltransferase.

### Claim 11 (depends on 10)

The nucleic acid molecule according to claim 10, wherein the histone methyltransferase is a histone-lysine N-methyltransferase selected from the group consisting of enhancer of zeste homolog 1 (EZH1), enhancer of zeste homolog 2 (EZH2), disruptor of telomeric silencing 1-like (DOT1-like), ASH1L, euchromatic histone-lysine N-methyltransferase 1 (EHMT1), euchromatic histone-lysine N-methyltransferase 2 (EHMT2), histone-lysine N-methyltransferase 2A, histone-lysine N-methyltransferase 2D (KMT2D), lysine N-methyltransferase 2C (KMT2C), myeloid/lymphoid or mixed-lineage leukemia 4 (MLL4), lysine methyltransferase 2E, and nuclear receptor binding SET domain protein 1 (NSD1). In other embodiments, the histone methyltransferase is a histone-arginine N-methyltransferases selected from the group consisting of protein arginine N-methyltransferase 1, protein arginine N-methyltransferase 3, protein arginine N-methyltransferase 4, protein arginine N-methyltransferase 5, and protein arginine N-methyltransferase 7.

### Claim 12 (depends on 2)

The nucleic acid molecule according to claim 2, wherein the protein of interest is a transcription factor.

### Claim 13 (depends on 12)

The nucleic acid molecule according to claim 12, wherein the transcription factor is selected from the group consisting of c-Myc, c-Fos, c-Jun, CREB, GATA-2, GAL4, GAL4Np16, c-Myb, MyoD, and NFκB, and TetR.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The nucleic acid molecule according to any one of claims 1-13, wherein the RNA-regulated destabilization domain is a bifunctional peptide comprising:
a lentiviral transactivator of transcription (Tat) peptide and
a degron peptide.

### Claim 15 (depends on 14)

The nucleic acid molecule according to claim 14, wherein the lentiviral transactivator of transcription (Tat) peptide has the amino acid sequence of SEQ ID NO: 54.

### Claim 16 (depends on 15)

The nucleic acid molecule according to claim 15, wherein the lentiviral transactivator of transcription (Tat) peptide has the amino acid sequence of SEQ ID NO: 55.

### Claim 17 (depends on 14)

The nucleic acid molecule according to claim 14, wherein the lentiviral transactivator of transcription (Tat) peptide comprises an RNA binding site corresponding to amino acid residues 4-17 of SEQ ID NO: 54 or amino acid residues 4-17 of SEQ ID NO: 55.

### Claim 18 (depends on 17)

The nucleic acid molecule according to claim 17, wherein the RNA binding site is specific for an RNA aptamer having the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

### Claim 19 (depends on 18)

The nucleic acid molecule according to claim 18, wherein the RNA binding site is specific for an RNA aptamer having the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

### Claim 20 (depends on 14)

The nucleic acid molecule according to claim 14, wherein the degron peptide is selected from the group consisting of a monopeptide, a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, a hexapeptide, a heptapeptide, and an octapeptide.

### Claim 21 (depends on 20)

The nucleic acid molecule according to claim 20, wherein the degron peptide is selected from the group consisting of P, E, RG, GG, EE, AP, RP, NP, DP, CP, EP, QP, GP, HP, IP, LP, KP, MP, FP, PP, SP, TP, WP, YP, VP, SA, SR, SN, SD, SC, SE, SQ, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, AN, RN, NN, DN, CN, EN, QN, GN, HN, IN, LN, KN, MN, FN, PN, SN, TN, WN, YN, VN, AD, RD, ND, DD, CD, ED, QD, GD, HD, ID, LD, KD, MD, FD, PD, SD, TD, WD, YD, VD, CA, CR, CN, CD, CC, CE, CQ, CG, CH, CI, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, AE, RE, NE, DE, CE, EE, QE, GE, RE, IE, LE, KE, ME, FE, PE, SE, TE, WE, YE, and VE.

### Claim 22 (depends on 14)

The nucleic acid molecule according to claim 14, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The nucleic acid molecule according to any one of claims 1-22 further comprising:
a third nucleic acid sequence encoding a second protein of interest, wherein the third nucleic acid sequence is located between the first nucleic acid sequence and second nucleic acid sequence.

### Claim 24 (depends on 17)

The nucleic acid molecule according to claim 17, wherein the second protein of interest is selected from the group consisting of a fluorescent protein, a bioluminescent protein, an enzyme, or a transcriptional regulator.

### Claim 25

A nucleic acid molecule encoding a lentiviral transactivator of transcription (Tar) RNA aptamer sequence.

### Claim 26 (depends on 25)

The nucleic acid molecule according to claim 25, wherein the nucleic acid molecule has the sequence of SEQ ID NO: 64, SEQ ID NO: 66, or SEQ ID NO: 68, wherein N can be A, C, G, or T; S can be C or G; H can be A, C, or T; Y can be C or T; W can be A or T; B can be C, G, or T; M can be A or C; and D can be A, G, or T.

### Claim 27 (depends on 25)

The nucleic acid molecule according to claim 25, wherein the nucleic acid molecule has the sequence of SEQ ID NO: 65, SEQ ID NO: 67, or SEQ ID NO: 69.

### Claim 28 (depends on 25)

The nucleic acid molecule according to claim 25, wherein the Tar RNA sequence is selected from the group consisting of (Pepper)10tag (SEQ ID NO: 60), (F30-1×Pepper)10tag (SEQ ID NO: 61), (Pepper)20tag (SEQ ID NO: 62), or (F30-2×Pepper)10tag (SEQ ID NO: 63).

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A vector comprising the nucleic acid molecule according to any one of claims 1-28.

### Claim 30 (depends on 29)

The vector according to claim 29, wherein the vector is selected from the group consisting of a plasmid, a phage, a transposon, a cosmid, a chromosome, and a virus.

### Claim 31 (depends on 29)

The vector according to claim 29, wherein the vector comprises the nucleic acid sequence of SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or SEQ ID NO: 79.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

An expression system comprising an expression vector into which is inserted a nucleic acid molecule according to any one of claims claim 1-28.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A host cell comprising the nucleic acid molecule of any one of claims 1-28 or the vector of any one of claims 29-32.

### Claim 34 (depends on 33)

The host cell of claim 33, wherein the host cell is a mammalian cell.

### Claim 35

An RNA-regulated fusion protein comprising a protein of interest and an RNA-regulated destabilization domain.

### Claim 36 (depends on 35)

The RNA-regulated fusion protein according to claim 35, wherein the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor.

### Claim 37 (depends on 35)

The RNA-regulated fusion protein according to claim 35, wherein the RNA-regulated destabilization domain has the sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

### Claim 38 (depends on 37)

The RNA-regulated fusion protein according to claim 37, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

### Claim 39

A molecular complex comprising:
an RNA-regulated fusion protein comprising
(i) a protein of interest and
(ii) an RNA-regulated destabilization domain; and
an RNA aptamer bound specifically to the RNA-regulated destabilization domain.

### Claim 40 (depends on 39)

The molecular complex according to claim 39, wherein the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor.

### Claim 41 (depends on 39)

The molecular complex according to claim 39, wherein the RNA-regulated destabilization domain has the sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

### Claim 42 (depends on 39)

The molecular complex according to claim 39, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

### Claim 43 (depends on 39)

The molecular complex according to claim 39, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

### Claim 44 (depends on 43)

The molecular complex according to claim 43, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

### Claim 45 (depends on 43)

The molecular complex according to claim 43, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

### Claim 46 (depends on 38, 39, 40, 41, 42, 43, 44, 45)

A host cell containing the molecular complex according to any one of claims 38-45.

### Claim 47 (depends on 46)

The host cell according to claim 46, wherein the host cell is a mammalian cell.

### Claim 48

A method of imaging RNA in a cell, said method comprising:
providing a first vector encoding an RNA-regulated fusion protein, wherein the RNA-regulated fusion protein comprises a fluorescent protein, a bioluminescent protein, or enzyme fused to an RNA-regulated destabilization domain;
providing a second vector encoding an RNA molecule comprising (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence;
transfecting the host cell with the first vector and the second vector; and
imaging said transfected cells.

### Claim 49 (depends on 48)

The method according to claim 48, wherein the RNA-regulated fusion protein is a fluorescent protein selected from the group consisting of Green Fluorescent Protein, Enhanced Green Fluorescent Protein (EGFP), Enhanced Yellow Fluorescent Protein (EYFP), Venus, mVenus, Citrine, mCitrine, Cerulean, mCerulean, Orange Fluorescent Protein (OFP), mNeonGreen, moxNeonGreen, mCherry, mTagBFP, Venus, mVenus, mTurquoise, mScarlet, mWasabi, mOrange, and dTomato.

### Claim 50 (depends on 48)

The method according to claim 48, wherein the RNA-regulated fusion protein is a bioluminescent protein selected from the group consisting of luciferase, β-galactosidase, β-lactamase, peroxidase, alkaline phosphatase, β-glucuronidase, and β-glucosidase.

### Claim 51 (depends on 48)

The method according to claim 48, wherein the RNA-regulated fusion protein is an enzyme and wherein the enzyme is a biotin ligase.

### Claim 52 (depends on 48)

The method according to claim 48, wherein the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

### Claim 53 (depends on 52)

The method according to claim 52, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

### Claim 54 (depends on 48)

The method according to claim 48, wherein the RNA of interest is a messenger RNA.

### Claim 55 (depends on 54)

The method according to claim 54, wherein the RNA aptamer sequence is located within a coding region of the mRNA.

### Claim 56 (depends on 54)

The method according to claim 54, wherein the RNA aptamer sequence is located upstream of the 5′ UTR, within the 5′ UTR, within the 3′ UTR, or downstream of the 3′ UTR.

### Claim 57 (depends on 48)

The method according to claim 48, wherein the RNA of interest is a noncoding RNA (ncRNA) selected from the group consisting of ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small cytoplasmic RNA (scRNA), small nuclear (snRNA), small nucleolar (snoRNA), ribozymes, and regulatory RNA.

### Claim 58 (depends on 48)

The method according to claim 48, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

### Claim 59 (depends on 48)

The method according to claim 48, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

### Claim 60 (depends on 48)

The method according to claim 48, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

### Claim 61

A method of imaging RNA in a cell, said method comprising:
providing a vector encoding an RNA-regulated fusion protein, wherein the RNA-regulated fusion protein comprises a fluorescent protein, a bioluminescent protein, or enzyme fused to an RNA-regulated destabilization domain;
transfecting the host cell with the first vector;
contacting said transfected cell with an RNA molecule comprising (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; and
imaging said contacted cells.

### Claim 62 (depends on 61)

The method according to claim 61, wherein the RNA-regulated fusion protein is a fluorescent protein selected from the group consisting of Green Fluorescent Protein, Enhanced Green Fluorescent Protein (EGFP), Enhanced Yellow Fluorescent Protein (EYFP), Venus, mVenus, Citrine, mCitrine, Cerulean, mCerulean, Orange Fluorescent Protein (OFP), mNeonGreen, moxNeonGreen, mCherry, mTagBFP, Venus, mVenus, mTurquoise, mScarlet, mWasabi, mOrange, and dTomato.

### Claim 63 (depends on 61)

The method according to claim 61, wherein the RNA-regulated fusion protein is a bioluminescent protein selected from the group consisting of luciferase, β-galactosidase, β-lactamase, peroxidase, alkaline phosphatase, β-glucuronidase, and β-glucosidase.

### Claim 64 (depends on 61)

The method according to claim 61, wherein the RNA-regulated fusion protein is an enzyme and wherein the enzyme is a biotin ligase.

### Claim 65 (depends on 61)

The method according to claim 61, wherein the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

### Claim 66 (depends on 65)

The method according to claim 65, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

### Claim 67 (depends on 61)

The method according to claim 61, wherein the RNA of interest is a messenger RNA.

### Claim 68 (depends on 67)

The method according to claim 67, wherein the RNA aptamer sequence is located within a coding region of the mRNA.

### Claim 69 (depends on 67)

The method according to claim 67, wherein the RNA aptamer sequence is located upstream of the 5′ UTR, within the 5′ UTR, within the 3′ UTR, or downstream of the 3′ UTR.

### Claim 70 (depends on 61)

The method according to claim 61, wherein the RNA of interest is a noncoding RNA (ncRNA) selected from the group consisting of ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small cytoplasmic RNA (scRNA), small nuclear (snRNA), small nucleolar (snoRNA), ribozymes, and regulatory RNA.

### Claim 71 (depends on 61)

The method according to claim 61, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

### Claim 72 (depends on 61)

The method according to claim 61, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

### Claim 73 (depends on 61)

The method according to claim 61, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

### Claim 74

A method of selectively modifying an RNA-binding protein, said method comprising:
providing a first expression vector encoding a RNA-regulated fusion protein, wherein the RNA-regulated fusion protein comprises an enzyme fused to a RNA-regulated destabilization domain;
providing a second expression vector encoding (i) a RNA sequence of interest and (ii) an RNA aptamer sequence, wherein the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence;
transfecting a host cell with the first and second expression vectors;
allowing the enzyme to be expressed, wherein the expressed enzyme selectively modifies a protein that binds to the RNA sequence of interest.

### Claim 75 (depends on 37)

The method according to claim 37, wherein the enzyme is selected from the group consisting of a ligase and a peroxidase.

### Claim 76 (depends on 74)

The method according to claim 74, wherein the enzyme is a biotin ligase selected from the group consisting of TurboID, miniTurbo, and E. coli BirA.

### Claim 77 (depends on 74)

The method according to claim 74, wherein the enzyme is a peroxidase selected from the group consisting of an ascorbate peroxidase and a horseradish peroxidase.

### Claim 78 (depends on 77)

The method according to claim 77, wherein the ascorbate peroxidase is APEX2.

### Claim 79 (depends on 74)

The method according to claim 74, wherein the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

### Claim 80 (depends on 79)

The method according to claim 79, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

### Claim 81 (depends on 74)

The method according to claim 74, wherein the RNA of interest is a messenger RNA.

### Claim 82 (depends on 81)

The method according to claim 81, wherein the RNA aptamer sequence is located within a coding region of the mRNA.

### Claim 83 (depends on 82)

The method according to claim 82, wherein the RNA aptamer sequence is located upstream of the 5′ UTR, within the 5′ UTR, within the 3′ UTR, or downstream of the 3′ UTR.

### Claim 84 (depends on 74)

The method according to claim 74, wherein the RNA of interest is a noncoding RNA (ncRNA) selected from the group consisting of ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small cytoplasmic RNA (scRNA), small nuclear (snRNA), small nucleolar (snoRNA), ribozymes, and regulatory RNA.

### Claim 85 (depends on 74)

The method according to claim 74, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

### Claim 86 (depends on 85)

The method according to claim 85, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

### Claim 87 (depends on 74)

The method according to claim 74, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

### Claim 88 (depends on 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method according to any one of claims 74-87, further comprising:
identifying a protein that is selectively modified by the enzyme within the transfected cells.

### Claim 89

A method of regulating expression of an RNA-stabilized protein of interest, said method comprising:
providing a first vector encoding an RNA-regulated fusion protein, wherein the RNA-regulated fusion protein comprises a protein of interest fused to an RNA-regulated destabilization domain;
providing a second vector encoding an RNA aptamer sequence, wherein the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence;
providing a host cell comprising a functional ubiquitination system;
transfecting the host cell with the first and second expression vectors; and
expressing the first and second expression vectors within the host cell, wherein said expressing the first and second expression vectors regulates proteomic stability of the RNA-regulated fusion protein; wherein, in the absence of any expressed RNA aptamer sequence in the host cell, the RNA-regulated destabilization domain promotes degradation of the RNA-regulated fusion protein by the ubiquitination system; and wherein the RNA-regulated fusion protein is stabilized by the expressed RNA aptamer sequence.

### Claim 90 (depends on 89)

The method according to claim 89, wherein the protein of interest is selected from the group consisting of a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor.

### Claim 91 (depends on 89)

The method according to claim 89, wherein the protein of interest is selected from the group consisting of a G-protein coupled receptor (GPCR), a nuclear receptor, a voltage gated ion channel, a ligand gated channel, a receptor tyrosine kinase, a growth factor, a phosphatase, a protein kinase, a viral regulator, a bacterial cell division protein, a scaffold protein, a DNA repair protein, a cytoskeletal protein, a ribosome, a histone deacetylase, an apoptosis regulator, a chaperone protein, a kinase, a phosphorylase, a phosphatase, deacetylase, a cytoskeletal protein (e.g., myosin, actin, dynein, kinesin, and tubulin).

### Claim 92 (depends on 89)

The method according to claim 89, wherein the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

### Claim 93 (depends on 92)

The method according to claim 92, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

### Claim 94 (depends on 89)

The method according to claim 89, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

### Claim 95 (depends on 94)

The method according to claim 94, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

### Claim 96 (depends on 89)

The method according to claim 89, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

### Claim 97 (depends on 89)

The method according to claim 89, wherein the host cells is a mammalian cell.

### Claim 98

A treatment method comprising:
contacting a cell with an RNA aptamer, wherein upon said contacting, the aptamer interacts with an RNA-regulated destabilization domain fused to a protein of interest in the cell to stabilize the protein of interest in the cell.

### Claim 99 (depends on 98)

The treatment method according to claim 98, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

### Claim 100 (depends on 98)

The treatment method according to claim 98, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

### Claim 101 (depends on 98)

The treatment method according to claim 98, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

### Claim 102 (depends on 98)

The treatment method according to claim 98, wherein the RNA-regulated destabilization domain has the sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

### Claim 103 (depends on 98)

The treatment method according to claim 98 further comprising:
introducing the protein of interest into the cell prior to said contacting.

### Claim 104 (depends on 103)

The treatment method according to claim 103, wherein the cell is in a patient.

### Claim 105 (depends on 104)

The treatment method according to claim 104, wherein said introducing is carried out by any one or more of injecting mRNA encoding for the protein of interest into the patient, injecting a plasmid encoding for the protein of interest into the patient, injecting the protein of interest into the patient, or systemically delivering the protein of interest into the patient.

### Claim 106 (depends on 104)

The treatment method according to claim 104, wherein the patient is a human.
